By Dr. Carlo Calabrese ND, MPH
Since 38% of US adults and 1 in 9 children use Complementary and Alternative Medicine (CAM) for a variety of health conditions, it behooves our society to attend to whether CAM products and practices are safe and effective. The public finds value in them. There are billions of users worldwide of what can be called CAM and millions of practitioners, often with long clinical traditions comprising enormous empirical databanks. People who use it aren’t stupid. Its practitioners are not entirely charlatans and the deluded.
CAM use is a variant of health care from orthodoxy. It is entirely reasonable that a society should spend its resources in the center of its epistemological orthodoxy. Funding of study of the “-omics” and much drug research is seen as well justified by informed CAM and CAM research advocates. But we are looking for new answers for intractable problems. Some of the future answers will be found in what is not now considered orthodox. This has happened many times in human history and will continue to happen. Thus, in a systematic search for novel solutions, it would be foolish to look at only a limited set of options with only a limited set of tools.
The proportion of dollars of research to care dollars spent is slanted steeply towards the funding the epistemology of orthodoxy, as we might expect. Even generously estimating $300 million for CAM research at NIH is just 1% of the NIH budget, a proportion that doesn’t reflect CAM use. The new funds for NCCAM in the recovery package are only 2/10 of 1% of the increase to NIH. Even critics indicate that most of this is arguably justified as most NIH CAM funding falls in journalist David Brown’s list of the “more plausible interventions.”
The irresponsibility is not in funding CAM research as suggested by its critics, but in putting it primarily in the hands of people like Dr. Salzberg who simply haven’t a very good idea of the range and character of CAM. “Reductionists” are interested in finding magic bullets while forgetting the basics. The basics, for example, are in health practice (the Obama administration calls it “wellness”), rather than disease practice. Measuring our progress towards health requires somewhat different tools— especially in clinical research— than measuring our distance from disease and death. Yet the grant application review system, even at NCCAM, is run by well-meaning orthodox scientists who don’t know the field and its potential and therefore support studies that are designed to answer the wrong questions. No wonder its performance disappoints Senator Harkin.
CAM practices, in reality, are many and diverse. How will we know what is worth studying and adopting if we don’t examine the “fringe” systematically. How will we know the field unless we attend to it as a category?
I am naturopathic physician and a scientist and have authored studies both positive and negative about CAM practices. The best CAM studies, the ones on the right questions, have provided evidence of the value of properly applied CAMs. These studies already call for change in current medical practice and policy.
With continued research at an appropriate level of funding, different CAM practices will either fall away or be integrated into general practice. This is what is happening now and what should be happening. Defunding NCCAM would be an abrogation of scientific and political responsibility.
{ 1 trackback }
{ 3 comments… read them below or add one }
This is really an interesting post…I enjoyed it…
You say you have authored studies both positive and negative about CAM practices, and that CAM studies have provided evidence of the value of properly applied CAMs. Can you provide me with some references to these studies?
Thanks.
As has been said recently, “This is not about me.” The studies with my involvement are a very few out of many thousands. That they show “negative” (showing no difference between groups) or positive treatment results merely provides data to be taken into consideration towards working conclusions. But since you ask, here are a few publications. I have some trepidation about putting up these examples, because some obsessive antagonist may attempt to dissect every statement in one or more of them and expect me to respond. I must warn in advance that I won’t. They all appeared in peer-review journals and the publications speak for themselves. If you disagree with our work and are a clinical scientist in the field, I encourage you to do your own study. If you choose to do so, you may find NIH NCCAM a valuable partner. I also realize that I’ve not answered the part of Rafe’squestion that asks for evidence that shows the value of properly applied CAMs, but will hold the treatise on what “properly applied” means for another hour. All the best.
“NEGATIVE”
Wahbeh H, Calabrese C, Zwickey H, Zajdel D. Binaural beat technology in humans: a pilot study to assess neuropsychological, physiological and EEG effects. J Altern and Comple Med 2007; 13(2):199-206
Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2824-30.
Blair DM, CS Hangee-Bauer, C Calabrese. Intestinal candidiasis, L. acidophilus supplementation and Crook’s questionnaire. J Naturopathic Medicine, 2(1):33-6, 1991.
POSITIVE
Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of Bacopa monnieri on cognitive performance, anxiety and depression in the elderly. J Altern & Comple Med Jul 2008; 14(6): 707-13.
Ritenbaugh C, Hammerschlag R, Calabrese C, Mist S, Aickin M, Sutherland E, Leben J, DeBar L, Elder C, Dworkin SF. A pilot whole systems clinical trial of traditional Chinese medicine and naturopathic medicine for the treatment of temporomandibular disorder. J Altern & Comple Med Jun 2008; 14(5):475-87.
Weber W, Taylor JA, VanderStoep A, Weiss NS, Standish LJ, Calabrese C. Echinacea purpurea for prevention of upper respiratory tract infections in children. J Altern and Comple Med 2005;11(6): 1021-6.
Calabrese C, P Preston. Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers. Planta Medica, 59(5):394-7, 1993.